Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
A novel series of cannabinoid ligands with a structurally unique tri-aryl core has been designed, synthesized and assayed. Receptor binding assays show that these compounds possess CB2 receptor sub-type selectivity with binding affinities ranging from 1.07 (+/-0.05) for 7 to 4.77 (+/-0.57) nM for 6. The selectivity of the compounds was enhanced 9-600-fold for the CB2 receptor over the CB1 receptor. The results of our present study identify a novel, highly selective cannabinoid scaffold with a non-classical core.
Bhattacharjee
Himanshu
H
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee-Memphis, TN 38163, USA.
Gurley
Steven N
SN
Moore
Bob M
BM
D001577:Benzophenones / Q000737:chemistry*; D001665:Binding Sites; D002186:Cannabinoids / Q000737:chemistry*; D002460:Cell Line; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D006801:Humans; D007249:Inflammation; D007700:Kinetics; D008024:Ligands; D008956:Models, Chemical; D015394:Molecular Structure; D043885:Receptor, Cannabinoid, CB2 / Q000737:chemistry* / Q000378:metabolism; D013237:Stereoisomerism; D014162:Transfection
D001577:Benzophenones; D002186:Cannabinoids; D008024:Ligands; D043885:Receptor, Cannabinoid, CB2; C000601178:SMM-189